Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Urovant Sciences Ltd. (UROV) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/08/2021 15-12B Form 15-12B - Securities registration termination [Section 12(b)]:
04/01/2021 EFFECT Form EFFECT - Notice of Effectiveness:
03/31/2021 4 Robinson James A. Jr. (PEO;CEO/Urovant Sciences, Inc.) has filed a Form 4 on Urovant Sciences Ltd.
Txns: Disposed/sold 8,385 shares @ $0
Disposed/sold 50,000 options to buy @ $12.41, valued at $620.5k
Disposed/sold 25,000 options to buy @ $8.78, valued at $219.5k
Disposed/sold 845,732 rights @ $9.16, valued at $7.7M
03/31/2021 4 Haag-Molkenteller Cornelia (CMO/Urovant Sciences, Inc.) has filed a Form 4 on Urovant Sciences Ltd.
Txns: Disposed/sold 11,603 shares @ $0
Disposed/sold 129,745 shares @ $0
Disposed/sold 146,850 options to buy @ $7.53, valued at $1.1M
Disposed/sold 1,000 options to buy @ $13.65, valued at $13.7k
Disposed/sold 100,000 options to buy @ $6.88, valued at $688k
03/31/2021 4 Legault Pierre (Director) has filed a Form 4 on Urovant Sciences Ltd.
Txns: Disposed/sold 12,480 shares @ $0
Disposed/sold 9,000 shares @ $0
Disposed/sold 13,350 options to buy @ $7.53, valued at $100.5k
Disposed/sold 36,650 options to buy @ $8.01, valued at $293.6k
Disposed/sold 25,000 options to buy @ $8.78, valued at $219.5k
Disposed/sold 15,000 options to buy @ $9.38, valued at $140.7k
03/31/2021 4 BANSAL AJAY (See Remarks) has filed a Form 4 on Urovant Sciences Ltd.
Txns: Disposed/sold 24,876 shares @ $0
Disposed/sold 115,222 shares @ $0
Disposed/sold 140,000 options to buy @ $9.66, valued at $1.4M
03/31/2021 4 Hindman James M. (Director) has filed a Form 4 on Urovant Sciences Ltd.
Txns: Disposed/sold 9,000 shares @ $0
Disposed/sold 61,000 options to buy @ $10.53, valued at $642.3k
Disposed/sold 15,000 options to buy @ $9.38, valued at $140.7k
03/31/2021 4 Kurstjens Sef (Director) has filed a Form 4 on Urovant Sciences Ltd.
Txns: Disposed/sold 12,480 shares @ $0
Disposed/sold 9,000 shares @ $0
Disposed/sold 13,350 options to buy @ $7.53, valued at $100.5k
Disposed/sold 36,650 options to buy @ $8.01, valued at $293.6k
Disposed/sold 25,000 options to buy @ $8.78, valued at $219.5k
Disposed/sold 15,000 options to buy @ $9.38, valued at $140.7k
03/31/2021 4 Johnston Walt (See Remarks) has filed a Form 4 on Urovant Sciences Ltd.
Txns: Disposed/sold 492 shares @ $0
Disposed/sold 108,647 shares @ $0
Disposed/sold 69,197 options to buy @ $10.64, valued at $736.3k
03/31/2021 4 Smith Bryan E. (GC/Urovant Sciences, Inc.) has filed a Form 4 on Urovant Sciences Ltd.
Txns: Disposed/sold 9,341 shares @ $0
Disposed/sold 115,106 shares @ $0
Disposed/sold 93,450 options to buy @ $7.53, valued at $703.7k
Disposed/sold 3,500 options to buy @ $13.65, valued at $47.8k
Disposed/sold 20,000 options to buy @ $6.88, valued at $137.6k
03/31/2021 4 OCAMPO CHRISTINE (PAO; CAO/Urovant Sciences,Inc.) has filed a Form 4 on Urovant Sciences Ltd.
Txns: Disposed/sold 9,810 shares @ $0
Disposed/sold 68,971 shares @ $0
Disposed/sold 133,500 options to buy @ $3.64, valued at $485.9k
Disposed/sold 3,750 options to buy @ $13.65, valued at $51.2k
Disposed/sold 70,000 options to buy @ $6.88, valued at $481.6k
03/31/2021 4 POTTER MYRTLE S (Director) has filed a Form 4 on Urovant Sciences Ltd.
Txns: Disposed/sold 12,480 shares @ $0
Disposed/sold 9,000 shares @ $0
Disposed/sold 50,000 options to buy @ $8.01, valued at $400.5k
Disposed/sold 25,000 options to buy @ $8.78, valued at $219.5k
Disposed/sold 15,000 options to buy @ $9.38, valued at $140.7k
03/30/2021 SC 13D/A Sumitomo Chemical Co., Ltd. reports a 100% stake in Urovant Sciences Ltd.
03/29/2021 SC 13E3/A Form SC 13E3/A - Going private transaction by certain issuers: [Amend]
03/29/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/29/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/29/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/29/2021 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/29/2021 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
03/29/2021 8-K Appointed a new director
Docs: "Amended and Restated Memorandum of Association of Urovant Sciences Ltd",
"Amended and Restated Bye-laws of Urovant Sciences Ltd",
"Sumitovant Biopharma Completes Acquisition of Urovant Sciences"
03/24/2021 8-K Submission of Matters to a Vote of Security Holders, Other Events
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : March 23, 2021 Urovant Sciences Ltd. Bermuda 001-38667 98-1463899 Suite 1, 3rd Floor 11-12 St. James's Square London SW1Y 4LB United Kingdom Not Applicable +44 207 400 3347 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-comm..."
02/19/2021 SC 13E3/A Form SC 13E3/A - Going private transaction by certain issuers: [Amend]
02/19/2021 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
02/16/2021 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/12/2021 10-Q Quarterly Report for the period ended December 31, 2020
02/12/2021 8-K Quarterly results
02/11/2021 8-K Quarterly results
02/09/2021 SC 13E3/A Form SC 13E3/A - Going private transaction by certain issuers: [Amend]
02/09/2021 8-K Quarterly results
02/04/2021 GN INVESTIGATION ALERT: Halper Sadeh LLP Investigates MDCA, NHLD, COHR, UROV; Shareholders Are Encouraged to Contact the Firm
02/02/2021 PRER14A Form PRER14A - Preliminary Proxy Soliciting materials:
01/25/2021 GN SHAREHOLDER ALERT: Halper Sadeh LLP Investigates UROV, WTRE, CBMG, NAV; Shareholders Are Encouraged to Contact the Firm
01/12/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/08/2021 GN MERGER INVESTIGATION: Halper Sadeh LLP Investigates CBMG, ALSK, UROV, NAV; Shareholders Are Encouraged to Contact the Firm
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy